-
公开(公告)号：US20110262348A1
公开(公告)日：2011-10-27
申请号：US13065794
申请日：2011-03-29
Applicant: Kiavash Movahedi , Damya Laoui , Steve Schoonooghe , Geert Raes , Patrick De Baetselier , Jo Van Ginderachter , Nick Devoogdt , Tony Lahoutte
Inventor： Kiavash Movahedi , Damya Laoui , Steve Schoonooghe , Geert Raes , Patrick De Baetselier , Jo Van Ginderachter , Nick Devoogdt , Tony Lahoutte
IPC: A61K39/395 , A61P35/00 , A61K51/10 , C07K16/28 , C12N11/02
CPC classification number: A61K51/1027 , A61K47/6829 , A61K47/6849 , A61K47/6899 , B82Y5/00 , C07K16/2851 , C07K2317/22 , C07K2317/35
Abstract: The present invention relates to the field of tumor growth and biology. The invention relates to activities and characteristics of tumor-associated macrophages, and uses of such for the diagnosis and treatment of cancer and tumor growth.
Abstract translation: 本发明涉及肿瘤生长和生物学领域。 本发明涉及肿瘤相关巨噬细胞的活性和特征，以及其用于诊断和治疗癌症和肿瘤生长的用途。
-
2.发明申请NOVEL ADIPOCYTOKINE VISFATIN/PBEF1 IS AN APOPTOSIS ASSOCIATED FACTOR INDUCED IN MONOCYTES DURING IN VIVO HIV-1 INFECTION 审中-公开新型ADIPOCYTOKINE VISFATIN / PBEF1是在HIV感染HIV感染期间诱发的单克隆抗体相关因子公开(公告)号：US20100184031A1
公开(公告)日：2010-07-22
申请号：US12451864
申请日：2008-06-05
Applicant: Geert Raes , Patrick De Baetselier , Rafael Van den Bergh , Guido Vanham
Inventor： Geert Raes , Patrick De Baetselier , Rafael Van den Bergh , Guido Vanham
IPC: C12Q1/68
CPC classification number: C12Q1/6883 , C12Q2600/158 , G01N33/56972 , G01N33/56988
Abstract: The present invention relates to the use of monocyte markers for diagnostic, prognostic or theranostic applications during diseases and syndromes caused by HIV infection. More specifically, it relates to a method comprising isolation of monocytes and determining gene expression, preferably PBEF1 gene expression. The method is useful to determine the evolution of the disease or can be used to evaluate the efficacy of a treatment.
Abstract translation: 本发明涉及单核细胞标志物在由HIV感染引起的疾病和综合征期间用于诊断，预后或应用的应用。 更具体地，涉及包含分离单核细胞并确定基因表达，优选PBEF1基因表达的方法。 该方法可用于确定疾病的进展或可用于评估治疗的功效。
-
公开(公告)号：US06936263B2
公开(公告)日：2005-08-30
申请号：US10222100
申请日：2002-08-16
Applicant: Hilde Revets , Pierre Cornelis , Patrick De Baetselier
Inventor： Hilde Revets , Pierre Cornelis , Patrick De Baetselier
IPC: A61K39/39 , A61P37/04 , C07K14/21 , C07K14/44 , C07K16/10 , A61K39/00 , A61K39/38 , A61K39/385 , A61K39/02 , A61K39/108 , A61K38/00 , A61K9/127 , C12N1/12 , C12P1/00 , C12P21/04
CPC classification number: A61K39/39 , A61K2039/523 , A61K2039/55544 , A61K2039/57 , C07K14/21 , C07K14/44 , C07K16/10 , C07K2319/00 , Y02A50/41 , Y10S424/823 , Y10S424/824 , Y10S424/825 , Y10S424/826 , Y10S424/828 , Y10S424/829
Abstract: The present invention relates to the use of the major OprI lipoprotein of Pseudomonas aeruginosa to elicit a Type-1 immune response towards a heterologous antigen. The invention relates specifically to the use of OprI—antigen fusion proteins to elicit the Type-1 response. More particularly, the present invention is directed to pharmaceutical formulations comprising OprI and/or OprI fusion proteins, optionally together with a suitable excipient, to stimulate the Th1 dependent, cellular immune response.
Abstract translation: 本发明涉及铜绿假单胞菌的主要OprI脂蛋白对异源抗原引起1型免疫应答的用途。 本发明具体涉及使用OprI-抗原融合蛋白引起1型反应。 更具体地，本发明涉及包含OprI和/或OprI融合蛋白的药物制剂，任选与合适的赋形剂一起刺激Th1依赖性细胞免疫应答。
-
公开(公告)号：US20050048060A1
公开(公告)日：2005-03-03
申请号：US10885492
申请日：2004-07-06
Applicant: Hilde Revets , Virna Cortez-Retamozo , Serge Muyldermans , Patrick De Baetselier
Inventor： Hilde Revets , Virna Cortez-Retamozo , Serge Muyldermans , Patrick De Baetselier
IPC: A61K47/48 , A61P35/00 , A61K39/395 , C07K16/30
CPC classification number: B82Y5/00 , A61K47/6853 , A61K47/6899
Abstract: The present invention relates to novel immunoconjugates that are devoid of light chains and comprise at least one variable domain of a heavy chain antibody. The immunoconjugates of the present invention can be used, for example, for the preparation of a medicament to treat tumors.
Abstract translation: 本发明涉及不含轻链的新型免疫偶联物，并且包含至少一个可变结构域的重链抗体。 本发明的免疫偶联物可用于例如制备治疗肿瘤的药物。
-
公开(公告)号：US09101674B2
公开(公告)日：2015-08-11
申请号：US13480350
申请日：2012-05-24
Applicant: Kiavash Movahedi , Damya Laoui , Steve Schoonooghe , Geert Raes , Patrick De Baetselier , Jo Van Ginderachter , Nick Devoogdt , Tony Lahoutte
Inventor： Kiavash Movahedi , Damya Laoui , Steve Schoonooghe , Geert Raes , Patrick De Baetselier , Jo Van Ginderachter , Nick Devoogdt , Tony Lahoutte
CPC classification number: A61K51/1027 , A61K47/6803 , A61K47/6813 , A61K47/6829 , A61K47/6849 , A61K47/6899 , A61K49/0002 , B82Y5/00 , C07K16/2851 , C07K2317/22 , C07K2317/35
Abstract: The invention relates to activities and characteristics of tumor-associated macrophages (TAMs). In particular, immunoglobulin single variable domains are provided against markers of TAMs, and methods using the same for in vivo imaging of tumor cells, as well as cancer diagnostics and therapeutics.
Abstract translation: 本发明涉及肿瘤相关巨噬细胞（TAM）的活性和特征。 特别地，针对TAM的标记提供免疫球蛋白单可变结构域，以及使用其免疫球蛋白单可变结构域用于肿瘤细胞的体内成像以及癌症诊断和治疗。
-
Patent Agency Ranking
公开(公告)号：US07514217B2
公开(公告)日：2009-04-07
申请号：US11371784
申请日：2006-03-09
Applicant: Geert Raes , Gholamreza Hassanzadeh Ghassabeh , Patrick De Baetselier
Inventor： Geert Raes , Gholamreza Hassanzadeh Ghassabeh , Patrick De Baetselier
CPC classification number: G01N33/5091 , G01N33/5094 , G01N2333/705
Abstract: The present invention relates to novel markers for alternatively activated macrophages. More specifically, the present invention relates to the use of galactose-type C-type lectins as surface markers that allows rapid identification and sorting of the alternative macrophages. Such identifications can be useful in diseases where there is an imbalance between proinflammatory and anti-inflammatory immune reactions.
Abstract translation: 本发明涉及交替活化的巨噬细胞的新型标记物。 更具体地，本发明涉及半乳糖型C型凝集素作为允许快速鉴定和分选替代巨噬细胞的表面标记物的用途。 这种鉴定可用于促炎和抗炎免疫反应之间不平衡的疾病。
-
公开(公告)号：US20070031430A1
公开(公告)日：2007-02-08
申请号：US11542714
申请日：2006-10-04
Applicant: Hilde Revets , Virna Cortez-Retamozo , Serge Muyldermans , Patrick De Baetselier
Inventor： Hilde Revets , Virna Cortez-Retamozo , Serge Muyldermans , Patrick De Baetselier
IPC: A61K39/395 , C12N9/00 , C07K16/30
CPC classification number: B82Y5/00 , A61K47/6853 , A61K47/6899
Abstract: The present invention relates to novel immunoconjugates that are devoid of light chains and comprise at least one variable domain of a heavy chain antibody. The immunoconjugates of the present invention can be used for the preparation of a medicament to treat tumours.
Abstract translation: 本发明涉及不含轻链的新型免疫偶联物，并且包含至少一个可变结构域的重链抗体。 本发明的免疫偶联物可用于制备治疗肿瘤的药物。
-
公开(公告)号：US20120301394A1
公开(公告)日：2012-11-29
申请号：US13480350
申请日：2012-05-24
Applicant: Kiavash Movahedi , Damya Laoui , Steve Schoonooghe , Geert Raes , Patrick De Baetselier , Jo Van Ginderachter , Nick Devoogdt , Tony Lahoutte
Inventor： Kiavash Movahedi , Damya Laoui , Steve Schoonooghe , Geert Raes , Patrick De Baetselier , Jo Van Ginderachter , Nick Devoogdt , Tony Lahoutte
CPC classification number: A61K51/1027 , A61K47/6803 , A61K47/6813 , A61K47/6829 , A61K47/6849 , A61K47/6899 , A61K49/0002 , B82Y5/00 , C07K16/2851 , C07K2317/22 , C07K2317/35
Abstract: The invention relates to activities and characteristics of tumor-associated macrophages (TAMs). In particular, immunoglobulin single variable domains are provided against markers of TAMs, and methods using the same for in vivo imaging of tumor cells, as well as cancer diagnostics and therapeutics.
Abstract translation: 本发明涉及肿瘤相关巨噬细胞（TAM）的活性和特征。 特别地，针对TAM的标记提供免疫球蛋白单可变结构域，以及使用其免疫球蛋白单可变结构域用于肿瘤细胞的体内成像以及癌症诊断和治疗。
-
9.发明申请Use of a polypeptide domain to modulate the tumorigenic and metastatic potential of cancer cells 审中-公开使用多肽结构域来调节癌细胞的致瘤和转移潜能公开(公告)号：US20080199472A1
公开(公告)日：2008-08-21
申请号：US12070239
申请日：2008-02-14
Applicant: Hilde Revets , Patrick De Baetselier , Nick Devoogdt , Gholamreza Hassanzadeh Ghassabeh
IPC: A61K39/395 , A61K38/00 , C12N5/06 , A61P43/00 , C12Q1/68
CPC classification number: A61K38/57
Abstract: The present invention reates to the use of a polypeptide domain to modulate the tumorigenic and metastatic potential of cancer cells. More specifically, the present invention relates to a domain of a Secretory Leukocyte Protease Inhibitor (SLPI) to modulate tumor invasiveness and/or metastasis. It further relates to compounds, such as antibodies, that interact with the domain and repress the tumor invasiveness and/or the metastasis.
Abstract translation: 本发明涉及使用多肽结构域来调节癌细胞的致瘤和转移潜能。 更具体地，本发明涉及调节肿瘤侵袭和/或转移的分泌性白细胞蛋白酶抑制剂（SLPI）的结构域。 它还涉及与结构域相互作用并抑制肿瘤侵袭和/或转移的化合物，例如抗体。
-
公开(公告)号：US4737455A
公开(公告)日：1988-04-12
申请号：US723100
申请日：1985-04-15
Applicant: Patrick De Baetselier
Inventor： Patrick De Baetselier
IPC: G01N33/52 , A61K35/12 , A61K35/28 , A61K38/16 , C12N5/02 , C12N5/10 , C12N5/16 , C12N15/02 , C12P21/08 , C12Q1/02 , C12R1/91 , G01N33/50 , G01N33/577 , C12N5/00 , G01N33/567 , G01N33/569
CPC classification number: C12N5/163 , G01N33/5005 , Y10S435/948 , Y10S435/968 , Y10S436/821
Abstract: The property of phagocyte cells to show chemiluminescence when activated by certain chemical or immunological agents is used for a qualitative and quantitative analysis of such agents in biological fluids. A variety of factors such as opsonizing anti-bodies, complement, inhibitors, membrane-specific anti-bodies, and their antigens, membrane-specific lectins, lymphokines, endotoxins, toxic substances and others can be analyzed in this way. The new method finds application in the biotechnical, clinical, immunological and pharmacological fields, with a special preference for toxicological screening of pharmaceuticals. The phagocyte cells needed for the analysis can be derived from a continuous phagocyte cell line and a method of producing such a cell line is provided.
Abstract translation: 吞噬细胞在被某些化学或免疫学试剂活化时显示化学发光的性质被用于生物流体中这些试剂的定性和定量分析。 可以分析各种因素，如调理抗体，补体，抑制剂，膜特异性抗体及其抗原，膜特异性凝集素，淋巴因子，内毒素，有毒物质等。 该新方法在生物技术，临床，免疫学和药理学领域得到应用，特别优选药物的毒理学筛选。 分析所需的吞噬细胞可以从连续的吞噬细胞系中获得，并且提供生产这样的细胞系的方法。
-
-
-
-
-
-
-
-
-
Search Results
15
records
(took 0.014 seconds)
